Chapter 41: Antitubercular Drugs

The bacterium's characteristic slow growth rate and formation of granulomas with caseated centers necessitate prolonged antimicrobial therapy extending six to twelve months to achieve cure and prevent relapse. Antitubercular medications are categorized into first-line agents, including isoniazid, rifampin, rifabutin, rifapentine, ethambutol, pyrazinamide, and streptomycin, which form the foundation of standard treatment regimens, and second-line agents reserved for drug-resistant infections. First-line agents are typically combined in four-drug regimens to reduce the emergence of antimicrobial resistance and optimize therapeutic outcomes. Each medication operates through distinct mechanisms including cell wall disruption, nucleic acid synthesis inhibition, lipid synthesis interference, and protein synthesis impairment. Critical nursing responsibilities encompass comprehensive baseline assessment including tuberculin skin testing, radiographic imaging, microbiological sampling, and laboratory evaluation of hepatic and renal function, as well as sensory assessments for baseline vision and hearing status. The chapter emphasizes significant adverse effects including hepatotoxicity from isoniazid, rifampin, and pyrazinamide; optic neuritis from ethambutol; ototoxicity and nephrotoxicity from aminoglycosides; peripheral neuropathy requiring pyridoxine supplementation; and cardiac effects requiring monitoring in patients receiving newer agents. Rifamycin medications produce distinctive discoloration of body secretions and induce hepatic enzyme systems, creating substantial drug interactions that compromise oral contraceptive efficacy and require alternative contraceptive counseling. Drug-resistant tuberculosis, including multidrug-resistant and extensively drug-resistant variants, demands second-line agents with increased toxicity profiles and requires meticulous adherence monitoring. Nursing practice focuses on patient education regarding treatment adherence, cultural sensitivity, family screening and prophylaxis, recognition of adverse effects, management of drug interactions with alcohol and other medications, infection control practices, and nutritional support throughout the extended treatment course.